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Project Summary
The application of bacteriophages to treat bacterial infections is known as phage therapy, which takes advantage
of bacteriophage’s natural ability to infect and lyse bacterial hosts. Phages have been shaped by billions of years
of evolution to be highly specialized deliverers of bactericidal agents to the cytoplasm of their target bacteria.
Ever since discovery of bacteriophages in 1915, phage therapy was recognized as a potentially powerful tool for
eliminating bacterial infections. The effectiveness of phage therapy can be increased by creating a mixture of
multiple phages to target a wider variety of bacterial strains. Furthermore, phage therapy has many advantages
over antibiotics. For example, phages replicate in vivo, so a smaller effective dose can be administered. Phages
will also stop reproducing once the target bacteria is destroyed. Much of the evidence strongly shows that, appropriately administered, phage therapy is effective for treatment of bacterial infectious diseases, especially
those caused by multidrug-resistant bacteria.
The worldwide spread of Klebsiella pneumoniae spp., which is resistance to a variety of antibiotics, threatens
to revert modern medicine to a pre-antibiotic era. Infections caused by drug-resistant K. pneumoniae spp. are
life threatening because of our limited ability to treat the associated disease symptoms. As a result, infections
due to multidrug resistant K. pneumoniae spp. have an extremely high mortality rate. The design of a phage
cocktail with potential therapeutic application against multidrug-resistant K. pneumoniae spp. may enable us
to respond to a rapidly emerging generation of multidrug-resistant bacterial species.
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Introduction
Basics of phage biology
Phages are naturally occurring viruses that specifically infect and lyse bacteria. The majority of reported
phages are tailed phages, composed of an icosahedral head and tail, and all of them have doublestranded DNA as the genome (Matsuzaki, 2005). Phages can be further classified into two groups
according to their life cycle. The lytic phage self-proliferates by intracellular development, maturation,
and finally release of virions from the host cell resulting in the death of the bacteria. But the lysogenic
phage integrates its phage genome into the bacterial genome, thereby allowing the phage genome to
multiply synchronously with the host bacteria without destroying it. The generic life cycle of a phage
begins with phage adsorption to a receptor on the bacterial surface, and then inserts phage DNA into
the bacterial cytoplasm. The DNA is replicated, synthesized, assembled, and released from the bacteria
(due to the lytic action of the proteins holin and endolysin), encoded by the phage genome, as shown
in Figure 1. (Young, 1992). Distinct phage isolates achieve antibacterial activity by differing in their
mechanism of entry or strategy of replication.
Phage therapy & its advantages
Phage therapy can be used for its lytic ability to control bacterial infection. There are multiple advantages
of phage therapy over conventional chemical antibiotics. For example, there is no need to establish
a dosage for phages because they are capable of replicating specifically where their hosts are located
(Carlton, 1999). This eliminates the need to determine an effective dose of the drug which may be
potentially dangerous if an excessive dose is administered. Only a single dose is required to achieve
active therapy, resulting in greater bacterial clearance (Abedon & Abedon, 2010). In addition, phage
therapy is minimally disruptive towards resident gut flora, unlike many chemical antibiotics, due to
their host specificity. Phage host specificity also reduces the potential for inducing resistance by limiting
the number of bacterial types, with which selection for specific phage-resistance mechanisms can occur
(Hyman & Abedon, 2010; Skurnik et al., 2007; Gupta & Yogendra, 2011). From an economic perspective,
the cost of phage production is relatively low compared with chemical antibiotics. Therapeutic phage
products would therefore be more readily available to the general public, in contrast to several of the
more expensive antibiotics available today (Skurnik et al., 2007; Kutter et al., 2010; Kramberger et
al., 2010). The effectiveness of phage therapy can be increased by expanding the host-range of phages,
because success depends largely on whether the phage can attach to the bacterial surface receptor. The
host range may be limited to just a subset of strains within a single species, or it may include a broad
range, spanning multiple bacterial genera (Hyman & Abedon, 2010).
Expanding host-range with phage cocktails
Phage infection can only occur after phage attachment to a bacterial cell receptor. Bacterial cell receptors
may include components of the O-antigen, outer core oligosaccharide of the lipopolysaccharide, and a
diversity of outer membrane proteins (Hashemolhosseini et al., 1994). Consequently, phage cocktails are
prepared to broaden host range because the recognition of bacterial receptors is not universal (Chan et
al., 2013). Phage cocktails are an amalgam of phages, each possessing different host ranges. Collectively,
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they expand the host-range to confer a broader spectrum of activity against infectious bacteria (Fig. 2).
Additionally, phage cocktails prevent the rapid emergence of phage-resistant strains. Bacteria may evolve
resistance to a specific phage, but it would be unrealistic for the bacteria to simultaneously develop
multiple resistance mechanisms to a collective group of phages (Goodridge, 2010; Tanji et al., 2005).
Recent advances of phage therapy
Currently, there are no commercially available therapeutic phages. The bulk of phage therapy research
is concentrated in Eastern Europe and Soviet Union. The US and Europe lost much of their interest in
phage therapy after the discovery of antibiotics, but Soviet research continued (Kutatekadze & Revaz,
2010). However, due to multidrug resistance, interest in phage therapy is increasing in the US and
Europe leading to several clinical trials as shown in Table 1. A Phase II clinical trial for phage therapy
was recently completed by Wright et al., who reported long-term positive results for ear infections,
burn wounds, and leg ulcers caused by Pseudomonas aeruginosa infections (Merril et al., 2003; Harper
& Enright, 2011). This demonstrates the effectiveness of phage therapeutics in P. aeruginosa, a bacterial
species that has evolved multidrug resistance.
While there are no current therapeutic applications of phages, the United States Food and Drug
Administration (FDA) has approved spraying meat with phages to eliminate Listeria monocytogenes,
a highly virulent food-borne pathogen that was the primary cause of listeriosis, in August 2006
(Ramaswamy, 2007). ListShield is a phage cocktail containing six listeria-specific phages designed to
attack a very broad spectrum of pathogenic L. monocytogenes strains. The phage preparation is sprayed
on food surfaces, and later consumed without any significant side effects. Strict phage-host specificity
targets only pathogenic L. monocytogenes strains. At the very least, this should demonstrate that direct
human use of phages is likely to be very safe (Mai et al., 2010).
Current therapeutic treatment options
Excessive use of antibiotics has reinforced selective pressure for antibiotic resistance, accelerating the
emergence of these “superbugs” (Drawz & Bonomo, 2010). As a result, our antibiotic armamentarium
is exhausted, severely restricting our ability to respond to new multidrug-resistant threats. The antibiotic
pipelines are nearly dry, failing to deliver novel antibiotics to match today’s multidrug resistance
crisis. Only two new classes of antibiotics have been developed in the past 3 decades (Theuretzbacher,
2012; Gupta & Nayak, 2014). Treatment options for multidrug-resistant infections are extremely
limited. While most isolates remain susceptible to colistin and tigecycline, their therapeutic viability
is questionable. Recurring infection after treatment with tigecycline increased the MIC (minimum
inhibitory concentration) significantly (Daly et al., 2007); colistin usage should be limited due to its
neurotoxicity and nephrotoxicity (Zavascki et al., 2007).
Targeting Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae with a phage
cocktail
Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae are becoming a growing menace
due to their resistance to β–lactam antibiotics and nearly all commercially available antibiotics; this
includes carbapenems, which are considered a drug of last resort against highly resistant microorganisms.
The enzyme K. pneumoniae carbapenemase was first discovered in K. pneumoniae but has since been
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found in other enterobacteriaceae. More than two million people are affected by antibiotic-resistant
infections with at least 23,000 deaths. They are a leading cause of nosocomial infections. The first KPCproducing K. pneumoniae outbreaks were reported in hospitals in New York City before spreading
globally to foreign healthcare environments (Bratu et al., 2005; Leavitt et al., 2007). KPC-producing K.
pneumoniae are responsible for an estimated 9,000 drug-resistant infections per year and 520 attributed
deaths (Bell et al., 2009). The attributable mortality rate due to KPC-producing K. pneumoniae
bacteremia infections is 50%, the highest reported so far for any microorganism causing bacteremia,
requiring more intensive patient care and exhausting the current antibiotic arsenal (Borer et al., 2009;
Patel et al., 2008).

Hypothesis
A phage preparation consisting of multiple phages specific to K. pneumoniae will successfully infect
and lyse bacterial host cells of various KPC-producing K. pneumoniae strains, due to the preparation’s
broad spectrum of activity.

Primary Objectives
• Screen fecal material obtained from the San Luis Obispo Wastewater Treatment facility as a source
of K. pneumoniae-specific phage and inoculate with several representative strains of K. pneumoniae
to perform a plaque assay.
• Isolate several phages based on their ability to produce lawns on the KPC-producing K. pneumoniae
host bacterium and identify and classify the phages.
• Propagate phages until the desired yield of amplification is attained, and then purify and precipitate
phages for use in in vitro assessments of its effectiveness.
• Test effectiveness by adding the phage cocktail to all KPC-producing K. pneumoniae strains grown in
culture, and assessing the phage cocktail’s ability to lyse the KPC-producing K. pneumoniae cultures.

Methods
Bacterial strain. Due to the moderate threat posed by the resistant K. pneumoniae strains, all microbial
cultures will be handled according to the appropriate safety procedures and precautions corresponding
to Biosafety Level 2 (Chosewood et al., 2009). Several representative strains (BAA-1705, BAA-1900,
BAA-2078, BA-2342, BAA-2343 and BAA-2344) of K. pneumoniae that produce the enzyme KPC will
be ordered from the American Type Culture Collection (ATCC) for phage isolation, amplification,
and evaluation. All strains are resistant to a broad spectrum of antibiotics, including carbapenems,
making them ideal models for the assessment of a phage cocktail. The strains will be grown at 37°C
in the supplied ATCC® Medium. This media contains nutrient agar (beef extract, peptone, and agar).
The strains will be stocked in nutrient broth containing 40% glycerol and stored at -80°C. Cultures
will be stored at 4°C and transferred periodically.
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Bacteriophage isolation and enrichment. Fecal material will be screened as a source for K. pneumoniae
strain-specific phages. Fecal samples will be obtained from the San Luis Obispo Wastewater Treatment
facility over a four month period. Portions of the samples will be added to volumes of early log-phase
K. pneumoniae (grown at 37°C) containing 10 mM CaCl2. These cultures will be incubated overnight
at 37°C with shaking (200 rpm). Samples will be withdrawn and centrifuged in a microcentrifuge for
5 min. The supernatant will be removed and passed through a sterilized filter before being subjected to
a plaque assay using K. pneumoniae as the host. Plaques appearing on lawns on the host bacteria will
be further processed to achieve desired phage stock of phage isolate candidates (Bourdin et al., 2013).
Phage morphology characterization. Identification and classification of phage candidates will be
determined by observing the morphology of the phages by transmission electron microscopy. Phage
particles will be sedimented at 25,000 g for 60 min. using a centrifuge, and then the phage particles
will be washed twice in ammonium acetate (pH 7.2) and deposited on copper grids provided with
carbon-coated Formvar films. They will be stained with 2% potassium phosphotungstate (pH 7.2) and
examined in a Philips EM 300 transmission electron microscope (Bourdin et al., 2013).
Phage amplification and purification. Phage candidates will be amplified in a 2-L Erlenmeyer flask
filled with 4 L of LB medium (grown at 37°C and pH maintained at 7.0 with NaOH 10%). The medium
will be inoculated with 3% of an overnight K. pneumoniae culture. At OD600 of 0.5, the bacteria
will be infected with the phage lysates at a multiplicity of infection of 1. The flask will be placed in an
incubator and shaken for 7 hours (400 rpm). Phages from the combined phage lysates will be separated
from organic debris by low speed centrifugation, and then by additional ultracentrifugation to pellet
the phages. The pellet will be re-suspended in phage buffer (150 mM NaCl and 10 mM Mg SO4 in
sterile water at pH 7.2) (Bourdin et al., 2013).
Phage cocktail testing. A 50 µl of K. pneumoniae ATCC BAA-1705, BAA-1900, BAA-2078, BA-2342,
BAA-2343 and BAA-2344 overnight culture will be inoculated into 5 ml of LB broth and incubated
with shaking at 37°C. The change of culture turbidity of OD660 will be automatically recorded by
photo recorder without fractionating the sample from the culture. When the culture reaches an OD660
of 0.1, the phage cocktail will be added at a multiplicity of infection of 10. The subsequent OD660
of the culture will be monitored. All assays will be performed in triplicate to confirm reproducibility
and assess the effectiveness of the phage cocktail (Tanji et al., 2005). The effectiveness of the phage
cocktail will be determined by measuring the optical density of the culture before and after treatment
with the phage cocktail.
Statistical analysis. The OD660 value of the bacterial culture before application of the phage cocktail
will be recorded for each strain. After the addition of the phage cocktail, the subsequent OD660 value
of the bacterial culture will be recorded. The mean OD660 values of the triplicate assay of all bacterial
strains will be used for data analysis. An independent two-sample t-test will be performed to determine
whether there is significant bacterial reduction after the application of a phage therapy. The data set
is assumed to be equal in sample size and variance because it is the same population of bacteria being
tested. Calculations will be performed in R, a free software programming for statistical computing. A
significant difference will suggest that application of a phage cocktail is effective in bacterial reduction,
and the opposite is true if there is no significant difference.
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Timeline
4
Phase
1
months

Phase
2

1
month

Phase 1
3
month

Phase
4

1
month

Budget

The undergraduate student researcher will be paid $10 per hour and will spend 10 hours a week for 7
months on this research project. The student will therefore be paid a total of $2800. KPC-producing
K. pneumoniae strains ordered from ATCC will cost $295 each, thus six strains of the bacteria will cost
$1,770 in total. All other equipment such as a spectrophotometer, ultracentrifuge, and a transmission
electron microscope will be available for use due to collaboration with the Biology and Biomedical
Engineering Department at California Polytechnic State University, San Luis Obispo. There will be
no travel costs associated with this research.
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Figure 1. This shows the infectious life cycle of bacteriophages. It begins with adsorption, injection of genetic
material, infection, and then the release of newly assembled bacteriophages.

Figure 2. This illustrates the benefit of using a cocktail of bacteriophages by broadening the host-range to
confer greater infectivity against multiple bacterial strains.

Table 1. This table highlights several recent investigations of bacterial reduction using phage cocktails.
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